Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million... -Today at 07:31 am- MarketScreener